stockrowInterpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024.
- Revenue
- −1.09%
- EPS
- +104.1%
- Free cash flow
- −92.1%
Quarter to June 2026, against a year earlier
Follow IDXG
Alert me
Interpace Biosciences, Inc. (IDXG) EV/Sales
As of 6 November 2026, Interpace Biosciences, Inc. (IDXG) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from 0.0× (July 2024) to 1.8× (February 2020); the current reading is higher than 86% of that period.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (47.04%) |
| FY2024 | 0.3× | 61.25% |
| FY2023 | 0.2× | (57.60%) |
| FY2022 | 0.4× | (67.90%) |
| FY2021 | 1.3× | 152.97% |
| FY2020 | 0.5× | (58.87%) |
| FY2019 | 1.2× | 0.00% |
| FY2018 | 1.2× | 0.00% |
| FY2017 | 1.2× | 0.00% |
| FY2016 | 1.2× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.3× | 5.02% |
| Mar 2026 | 1.2× | 700.00% |
| Dec 2025 | 0.1× | 15.75% |
| Sep 2025 | 0.1× | 3.53% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IDXG Interpace Biosciences, Inc. | 1.1× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)